RV41.F Fennec Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
9.25 EUR
Close of Nov 13, 2026
4.74 11.10
Market cap
EUR 324M
P/E
-
P/B
8.81x
ROE
10.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is RV41.F undervalued?

Graham number

The Graham number of Fennec Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Fennec Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Fennec Pharmaceuticals Inc yet.

Fennec Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clini…

Full company profile